Drug Search Results
More Filters [+]

Celivarone

Alternative Names: celivarone
Latest Update: 2016-05-30
Latest Update Note: Clinical Trial Update

Product Description

Celivarone, a new noniodinated benzofuran derivative pharmacologically related to dronedarone and amiodarone, has been shown to have antiarrhythmic properties at a molecular level.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22171925/)

Mechanisms of Action: ADRB1 Blocker,Potassium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Celivarone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Atrial Fibrillation|Atrial Flutter

Phase 2: Atrial Flutter|Atrial Fibrillation|Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ALPHEE

P2

Completed

Unknown

2011-05-12

ALPHEE

P2

Completed

Other

2011-05-01

MAIA

P3

Completed

Atrial Flutter|Atrial Fibrillation

2006-05-01

CORYFEE

P2

Completed

Atrial Fibrillation|Atrial Flutter

2006-04-01

Recent News Events

Date

Type

Title